Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant ...

Following a high-profile trip to the Middle East and progress in trade talks with China, polling indicates that perceptions ...

The fundamental distinction between negative and positive rights is essential to a proper understanding of the First Amendment. Consider how the law treats public museums. It's well understood ...

EMA committee recommends approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer: Basel Monday, May 26, 2025, 12:00 Hrs [IST] Roche an ...

The USD/CAD pair posts modest gains near 1.3805 during the early Asian session on Wednesday. The US Dollar (USD) strengthens ...

Our weekly simulation for U.S. Treasury yields. Read the latest update in the article series, as of May 23, 2025.

Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

REVEAL GENOMICS, S.L., a biotechnology company advancing precision oncology through biomarker innovation, today announced the ...

The London Company Income Equity portfolio returned 4.6% during the quarter vs. a 2.1% increase in the Russell 1000 Value ...

LSG, who failed to secure a playoff berth this season, are using their next fixture as an opportunity to reflect on the ...

Patients with CSCC who had lymphovascular invasion had a greater incidence of metastasis and disease-specific death than those without.